COR2ED - Oncology Medical Conversation Video

COR2ED - Oncology Medical Conversation Video

By COR2ED Medical EducationScienceMedicineHealth & FitnessEducationCourses
Download on the App Store

COR2ED - Oncology Medical Conversation Video episodes

  • Think Narcolepsy: Why Early Recognition and Referral Matter

    Join experts Dr Markus Schmidt and Dr Anna Heidbreder as they discuss the importance of early recognition and referral in narcolepsy type 1 (NT1), particularly as new targeted treatments begin to emerge. 

    Key discussion points include: 

    • Emerging therapies: How OX2R agonists may transform narcolepsy care, with Phase 3 overporextin data showing significant improvements in wakefulness and cataplexy with no serious AEs reported. 
    • Diagnostic red flags: Recognising excessive daytime sleepiness, cataplexy, sleep paralysis, and hallucinations to help reduce the current 7–10 year delay in diagnosis. 
    • Clinical pitfalls: Avoiding common misdiagnoses, such as attributing symptoms to lifestyle-related fatigue in younger patients or sleep apnoea in older adults. 
    • Specialist referral: The importance of timely referral for specialist assessment and objective sleep testing to support earlier access to emerging therapies. 

      • By identifying these symptom clusters earlier, clinicians may improve long-term outcomes and quality of life for people living with NT1. 

       

      Key clinical takeaways:  

      • New treatment options are emerging: OX2R agonists represent a shift toward targeting the underlying biology of NT1, with the potential to significantly improve patient outcomes 
      • Early recognition is critical: Narcolepsy is often under-recognised and misdiagnosed, so clinicians should maintain a high index of suspicion, particularly in patients with excessive daytime sleepiness 
      • Act early and refer appropriately: Timely referral to specialists is essential to confirm diagnosis, optimise management, and ensure patients can benefit from current and emerging therapies 

        • You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/sleep-connect/programmes/narcolepsy-early-recognition-referral/?media=0 

        Or watch on YouTube: https://youtu.be/jHgORhjB_lw 

        Follow us on social media: 

        LinkedIn: https://www.linkedin.com/company/sleep-connect/about/ 

        X: https://x.com/SleepConnect_  

        Instagram: https://www.instagram.com/cor2edmeded  

         

        This content is intended for healthcare professionals only. 

        This podcast is supported by an Independent Education Grant from Takeda  

         

        This podcast is developed by cor2ed.com 

        Published May 2026 

         

        Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

        18 min
      • Pre-analytical phase challenges and biomarker testing in HER2+ metastatic breast cancer

        Pre-analytical Phase Challenges and Biomarker Testing in HER2+ Metastatic Breast Cancer 

         

        Key clinical takeaways:  

        • Metastatic breast cancer (mBC) is a complex, heterogeneous disease requiring multidisciplinary collaboration. Pathologists are central to this process to ensure accurate interpretation and optimal patient management   
          • Incorporating HER2-low and HER2-ultralow categories in biomarker testing is critical for mBC due to the demonstrated efficacy of HER2-targeted antibody-drug conjugates, such as trastuzumab deruxtecan, in these patient subsets, expanding therapeutic options beyond traditional HER2-positive cases   
            • High-quality pre-analytical handling and nuanced interpretation are essential for accurate HER2 classification, particularly for HER2-low and –ultralow disease. Small errors in testing or interpretation can lead to missed treatment opportunities. 

              •  

               

              This is the full video. Watch the shorter highlights video here: https://cor2ed.com/precision-oncology-connect/programmes/biomarker-testing-breast-cancer/?media=0 

               

              Listen to the audio version of this conversation on Spotify, Apple, or on the COR2ED website, where you can also download the accompanying one-page snapshot: https://cor2ed.com/precision-oncology-connect/programmes/biomarker-testing-breast-cancer/?media=2 

                

              Follow us on social media: 

              LinkedIn: https://linkedin.com/company/ntrk-connect 

              X: https://x.com/PresOnc_Connect 

               

              This content is intended for healthcare professionals only.  

              This video is supported by an Independent Education Grant from Daiichi Sankyo. 

               

              This video is developed by cor2ed.com 

              Published on March 2026. 

               

              Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

              24 min
            • Metastatic breast cancer: Understanding HER2-low and HER2-ultralow classification

              Understanding HER2-low and HER2-ultralow classification in mBC


              In this video podcast moderated by the Oncology Brothers, Dr Komal Jhaveri provides a practical overview of how this shift beyond a binary HER2 model translates into everyday clinical practice.

              The experts explore:

              • Key efficacy data from DESTINY-Breast04 and DESTINY-Breast06, and their impact on the HER2 treatment framework
              • The clinical relevance of HER2-low and HER2-ultralow categories, and review the CAP reporting template
              • When and why to perform re-biopsy to detect changes in HER2 expression over time
              • Best practices for monitoring and managing T-DXd–related adverse events, including nausea, vomiting, fatigue and ILD/pneumonitis

                •  

                Watch now to deepen your understanding of HER2-low and HER2-ultralow classification, refine how and when you test, and appreciate the impact on therapeutic decision-making in mBC.

                 

                Clinical takeaways

                 

                • DESTINY-Breast04 and DESTINY-Breast-06 established T-DXd as an effective option for HER2-low and HER2-ultralow mBC, improving PFS and OS and showing that even minimal HER2 expression can identify patients who benefit from T-DXd
                • Current CAP reporting template separates HER2-low (IHC 1+ or 2+/ISH–) and HER2-ultralow (IHC 0 with faint or incomplete membrane staining in ≤10% of tumour cells) from true HER2-0, creating treatment-defining strata for HER2-targeted ADCs such as T-DXd
                • Because HER2 expression is dynamic between primary and metastatic sites and over time, re-biopsy at progression, particularly in tumours previously scored as HER2-0, should be considered to identify new candidates for T-DXd
                • T-DXd delivers substantial antitumour activity, but treatment-related adverse events, including nausea, vomiting, fatigue, alopecia and, in particular, ILD/pneumonitis, require careful and proactive management. Clinicians should apply structured supportive care and early, vigilant monitoring to ensure safe and sustained treatment

                  •  

                   

                   

                  This is the full video. Watch the shorter highlights video here: https://youtu.be/3xepcF70Ljw

                   

                  Listen to the audio version of this conversation on Spotify, Apple, or on the COR2ED website

                   

                  Follow us on social media:

                  LinkedIn: https://www.linkedin.com/company/breastcancerconnect/

                  X: https://x.com/BreastCaConnect

                   

                  This content is intended for healthcare professionals only.

                   

                  This programme is supported by an Independent Education Grant from AstraZeneca.

                  This podcast is developed by cor2ed.com

                   

                  Published December 2025

                   

                  Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

                  26 min
                • Understanding EP-NEC: Through Diagnosis, Treatment, and Support

                  In this podcast, Medical Oncologist, Dr Aman Chauhan and Neuroendocrine Patient Advocate, Susan Meckler-Plummer, discuss extrapulmonary high-grade neuroendocrine carcinomas (EP-NECs), a rare, aggressive, and often misunderstood subset of neuroendocrine cancers.  

                  They clarify the crucial differences between NETs and NECs, explain why accurate classification and rapid treatment are essential, and highlight current and emerging therapeutic approaches, including DLL3-targeted therapies.  

                  Through both HCP and patient-centred perspectives, the conversation addresses real-world challenges, the importance of support networks, and the growing sense of hope for people affected by this difficult disease. 

                  Key clinical takeaways:  

                  • Unlike NETs, EP-NECs are poorly differentiated, high-grade, aggressive, and fast-growing cancers, with a need for more effective treatments
                    • While there remains a medical need for effective treatment of EP-NECs, clinical studies with DLL3-targeted agents show promise 
                      • Accessing a support network can provide emotional reinforcement and information for patients and their care partners 

                        •  

                        You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/net-connect/programmes/ep-nec-diagnosis-treatment-support/?media=0 

                        Or watch on YouTube: https://youtu.be/nfng2s3jSw8 

                        Follow us on social media: 

                        LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect/?viewAsMember=true  

                        X:https://x.com/net_connectinfo 

                        This podcast is supported by an Independent Education Grant from Boehringer Ingelheim.

                        This podcast is developed by cor2ed.com 

                        Published in November 2025 

                         

                        Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

                        28 min
                      • Exploring the role of targeted radiopharmaceutical treatment in NETs

                        How are advances in radioligand therapy shaping the treatment of neuroendocrine tumours, and what does recent trial evidence tell us? What are the key considerations for patient selection, sequencing, and safety? 

                        In this podcast moderated by the Oncology Brothers, Drs Rohit and Rahul Gosain are joined by medical oncologist Dr Heloisa Soares and nuclear medicine physician Prof. Ken Herrmann to explore the evolving role of targeted radioligand therapy in NETs. 

                        As the conversation unfolds, the experts discuss evidence from recent studies, including the COMPETE trial, share practical insights on multidisciplinary decision-making, and highlight future directions such as the potential for first-line treatment with radioligand therapy. 

                        Key clinical takeaways:  

                        • Pair the right patient with the right treatment using an understanding of the key clinical studies 
                          • The role of PRRT as a very effective 2nd-line treatment was consolidated by the COMPETE study data  
                            • The best outcomes are achieved through multi-disciplinary collaborations that include the patient 

                              •   

                              Listen to the audio version of this conversation on Spotify, Apple, or on the COR2ED website, where you can also download the accompanying transcript and infographic: https://cor2ed.com/net-connect/programmes/targeted-radiopharmaceutical-treatment-nets/?media=0

                               

                              Follow us on social media: 

                              LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect/?viewAsMember=true  

                              X: https://x.com/net_connectinfo  

                              This content is intended for healthcare professionals only. 

                              This podcast is supported by an Independent Education Grant from ITM.  

                              This podcast is developed by cor2ed.com 

                               

                              Published September 2025 

                              22 min
                            • Exploring the role of targeted radiopharmaceutical treatment in NETs

                              How are advances in radioligand therapy shaping the treatment of neuroendocrine tumours, and what does recent trial evidence tell us? What are the key considerations for patient selection, sequencing, and safety? 

                              In this podcast moderated by the Oncology Brothers, Drs Rohit and Rahul Gosain are joined by medical oncologist Dr Heloisa Soares and nuclear medicine physician Prof. Ken Herrmann to explore the evolving role of targeted radioligand therapy in NETs. 

                              As the conversation unfolds, the experts discuss evidence from recent studies, including the COMPETE trial, share practical insights on multidisciplinary decision-making, and highlight future directions such as the potential for first-line treatment with radioligand therapy. 

                              Key clinical takeaways:  

                              • Pair the right patient with the right treatment using an understanding of the key clinical studies 
                                • The role of PRRT as a very effective 2nd-line treatment was consolidated by the COMPETE study data  
                                  • The best outcomes are achieved through multi-disciplinary collaborations that include the patient 

                                    •   

                                    Listen to the audio version of this conversation on Spotify, Apple, or on the COR2ED website, where you can also download the accompanying transcript and infographic: https://cor2ed.com/net-connect/programmes/targeted-radiopharmaceutical-treatment-nets/?media=0

                                     

                                    Follow us on social media: 

                                    LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect/?viewAsMember=true  

                                    X: https://x.com/net_connectinfo  

                                    This content is intended for healthcare professionals only. 

                                    This podcast is supported by an Independent Education Grant from ITM.  

                                    This podcast is developed by cor2ed.com 

                                     

                                    Published September 2025 

                                    22 min
                                  • Tackling mPDAC: chemotherapy strategies that matter

                                    Metastatic pancreatic ductal adenocarcinoma (mPDAC) is notoriously aggressive with a poor prognosis. It is often diagnosed late, and by this time, surgery is usually not an option. Median overall survival without treatment is just a few months but with systemic chemotherapy this can be improved.   

                                    This video includes the highlights from a video podcast where medical oncologists Prof Shubham Pant and Prof Efrat Dotan discuss how to choose and optimise the different chemotherapeutic options at first and second line. 

                                    Key clinical takeaways: 

                                    • mPDAC is notoriously aggressive with a poor prognosis. Patients are generally diagnosed with advanced-stage disease and require treatment with chemotherapy as soon as possible
                                    • Frontline regimens should be individualised based on performance status, comorbidities, and risk of neuropathy; FOLFIRINOX, NALIRIFOX, and gemcitabine/nab-paclitaxel all offer survival benefit with distinct toxicity profiles
                                    • Choice of 2nd line treatment should be guided by prior regimen and patient fitness
                                    • Dose modification and alternative scheduling are standard in real-world practice and are used to maintain dose intensity while improving tolerability and reducing adverse events

                                      • You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/gi-connect/programmes/tackling-mpdac/?media=0 

                                      Or watch on YouTube: https://youtu.be/8YxRnjOYUv4 

                                      Follow us on social media: 

                                      LinkedIn: https://www.linkedin.com/company/giconnect 

                                      X: https://x.com/giconnectInfo 

                                      This content is intended for healthcare professionals only. 

                                      The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution.  This podcast is supported by an Independent Education Grant from Ipsen USA. 

                                      This podcast is developed by cor2ed.com 

                                      Published May 2025 

                                      Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

                                      22 min
                                    • Understanding Rare NSCLC Mutations: Insights, access and support

                                      Listen to a revealing conversation between Dr Joshua Sabari, a Medical Oncologist specialising in the treatment of rare alternations of NSCLC and Debra Montague, President of Lung Cancer Europe (LuCE) and founder of ALK Positive UK.   

                                      As a patient advocate as well as a patient herself, Debra brings a wealth of experience and depth of insight into the discussion with Dr Sabari.   

                                      Dr Sabari shares his clinical knowledge regarding diagnosis, biomarker testing and treatment of such alterations, together with his own first-hand experience of treating and empowerig patients like Debra in their own treatment journey. 

                                      What does the patient pathway look like from both perspectives?  What are the needs of Medical Oncologists and patients when navigating the treatment journey?  What do patients need from their oncologists?  What do oncologists think their patients need from them?  Are these needs matched by the support currently available?   

                                      You can also watch a video of the experts in conversation and download the transcript on our website: https://cor2ed.com/lung-connect/programmes/understanding-rare-nsclc-mutations/?media=0 

                                      Or watch on YouTube: https://www.youtube.com/watch?v=Z57cUtQx1BE&t 

                                       

                                      Follow LUNG CONNECT on social media: 

                                      X – https://x.com/lung_connect  

                                      LinkedIn – https://www.linkedin.com/company/lungconnect/  

                                      This content is intended for healthcare professionals only. 

                                      The experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution.  This podcast is supported by an Independent Education Grant from Boehringer Ingelheim. 

                                       

                                      This podcast is developed by cor2ed.com 

                                      Published on May 2025 

                                       

                                      Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

                                      21 min
                                    • The HER2 diagnostic and treatment landscape in NSCLC

                                      Episode 2: Navigating common treatment scenarios in HER2-mutant NSCLC 

                                      This is the second episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC, hosted by the Oncology Brothers, Drs Rohit and Rahul Gosain.   

                                      In this episode Drs Isabel Preeshagul and Eric Singhi provide the benefit of their experience when discussing how to approach different treatment scenarios in HER2-mutant NSCLC. 

                                      The conversation unfolds to cover; 

                                      • How to distinguish HER2 alterations from other alterations on biomarker reports 
                                        • The latest efficacy and safety data of currently approved and emerging treatments for HER2-altered NSCLC  
                                          • The potential CNS activity of these treatments in patients with HER2-mutated NSCLC 
                                            • How the treatment pathway may look in the near future 

                                              • You can also watch a video of the experts in conversation and download the transcript on our website: https://cor2ed.com/lung-connect/programmes/her2-diagnostic-treatment-nsclc-2/

                                              Or watch on YouTube: https://youtu.be/E8-3GDyJT9Y

                                               

                                              Follow LUNG CONNECT on social media: 

                                              X – https://x.com/lung_connect  

                                              LinkedIn – https://www.linkedin.com/company/lungconnect/  

                                              This content is intended for healthcare professionals only. 

                                              The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution.  This podcast is supported by an Independent Education Grant from Bayer. 

                                               

                                              This podcast is developed by cor2ed.com 

                                              Published on May 2025 

                                               

                                              Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

                                              19 min
                                            • The HER2 Diagnostic and Treatment Landscape in NSCLC

                                              Episode 1: Identifying HER2-directed NSCLC: The Medical Oncologist and Pathologist perspectives 

                                              This is the first episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC, hosted by the Oncology Brothers, Drs Rohit and Rahul Gosain.   

                                              What makes this conversation so interesting, is that you can gather insights from both the Medical Oncologist perspective with Dr Devika Das, and pathology perspective from Prof. Lopéz-Ríos. 

                                              In this episode the discussion focuses identifying HER2-directed NSLC, considering mutations, overexpression and amplifications, whilst not forgetting how best practice in identification of HER2 alterations may be translated in the community setting. 

                                              Listen to different expert perspectives on 

                                              • The different HER2 alterations and prevalence in NSCLC 
                                                • Which technique to identify which HER2 alteration 
                                                  • HER2-targeted treatments, both approved and in development 

                                                    •  

                                                    You can also watch a video of the experts in conversation and download the transcript on our website: https://cor2ed.com/lung-connect/programmes/her2-diagnostic-treatment-nsclc-1/?media=1 

                                                    Or watch on YouTube: https://youtu.be/3vMCzR1jqbI 

                                                     

                                                    Follow LUNG CONNECT on social media: 

                                                    X – https://x.com/lung_connect  

                                                    LinkedIn – https://www.linkedin.com/company/lungconnect/  

                                                     

                                                    This content is intended for healthcare professionals only. 

                                                    The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution.  This podcast is supported by an Independent Education Grant from Bayer. 

                                                     

                                                    This podcast is developed by cor2ed.com 

                                                    Published on April 2025 

                                                     

                                                    Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

                                                    22 min

                                                  About COR2ED - Oncology Medical Conversation Video

                                                  From the publisher's feed

                                                  Join oncology experts as they discuss their approaches to diagnosing and managing patients with gastrointestinal, genitourinary, lung, breast, gynecological, neuroendocrine and hematological cancers, sarcomas, and more. The conversations also explore cutting edge developments in precision oncology, as well as emerging treatments, including immunotherapy.